ATUM

Company Overview

Atum, founded in 2003, manufactures and markets synthetic DNA products, and is a leading provider of synthetic genes. Key end-user markets for Atum synthetic-gene products include biotechnology, large pharmaceutical companies, the chemical industry, and academia.

Synthetic genes have key advantages over naturally produced cloned genes, including fast and low-cost synthesis; furthermore, they are easily modified to optimize downstream manipulations, they have improved protein expression (from 10 to 100 times greater yields) and they have the flexibility for any sequence. The reason that synthetic genes can express more protein than a native gene is that native genes evolved for balanced expression of all genes within the cell and not for high expression of any single gene. Cloning costs include the purchase of oligonucleotides and molecular biology kits, labor, and sequencing. Purchasing synthetic genes is often much less expensive than cloning.

Atum has its proprietary gene optimization and synthesis platforms namely GeneGPS and VectorGPS. These platforms are used to design DNA constructs that can be optimized to express across various systems, i.e., from a single gene in E. Coli to complex mammalian cells.

Atum’s GeneGPS Expression Optimization technology is a codon-optimization algorithm that gives high protein expression. This performance level gives Atum a key advantage in this market.

Through its RUSH Gene Synthesis Service, the company claims to be the fastest and most reliable gene synthesis turnaround time provider in the industry.

Company's Business Segments

• Products : Expression Vectors, CRISPR, Cas9, Reagents, Strains
• Services : DNA 2.0 Gene Design and Synthesis Services, Antibody Services, Cell Line Development, Protein Expression Services, cGMP Cell Banking, Biological Engineering, Protein Engineering